Osterweis Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Osterweis Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-89,726	Closed	-$7.6M	–	111
2018 Q4	$7.6M	Buy	89,726 +42,383	+90%	+$4.52M	0.58%	52
2018 Q3	$8.11M	Buy	47,343 +192	+0.4%	+$28.9K	0.52%	58
2018 Q2	$6.09M	Sell	47,151 -19,524	-29%	-$2.18M	0.39%	55
2018 Q1	$6.87M	Buy	66,675 +11,173	+20%	+$1.1M	0.49%	46
2017 Q4	$4.74M	Sell	55,502 -8,216	-13%	-$712K	0.34%	48
2017 Q3	$5.41M	Buy	63,718 +1,155	+2%	+$91.5K	0.41%	43
2017 Q2	$4.74M	Buy	62,563 +13,545	+28%	+$948K	0.36%	43
2017 Q1	$3.24M	Sell	49,018 -12,407	-20%	-$816K	0.25%	54
2016 Q4	$3.89M	Buy	+61,425	New	+$3.88M	0.28%	46

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Osterweis Capital Management's LGND Position: Q1 2019 in Review

Osterweis Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 89,726 shares — an estimated $7.6M sold.

Osterweis Capital Management first reported a position in LGND in Q4 2016 and held it in 9 quarters. The position peaked at $8.11M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Osterweis Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Osterweis Capital Management sold 89,726 Ligand Pharmaceuticals shares in Q1 2019, an estimated $7.6M.
Osterweis Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 9 quarters.
Osterweis Capital Management's Ligand Pharmaceuticals position peaked at $8.11M in Q3 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Osterweis Capital Management's 13F filing for Q1 2019, filed 15 May 2019.